NextCure, Inc. (NXTC)
NASDAQ: NXTC · IEX Real-Time Price · USD
1.485
-0.045 (-2.94%)
Apr 24, 2024, 2:03 PM EDT - Market open

NextCure Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Revenue
00022.386.3500
Revenue Growth (YoY)
---252.58%---
Gross Profit
00022.386.3500
Selling, General & Admin
19.7121.7120.5717.059.613.412.6
Research & Development
47.9354.250.1946.5534.2219.7912.95
Operating Expenses
67.6475.9170.7763.643.8323.215.55
Operating Income
-67.64-75.91-70.77-41.23-37.48-23.2-15.55
Other Expense / Income
-4.91-1.18-1.38-4.62-3.75-0.4-0.08
Pretax Income
-62.72-74.73-69.39-36.6-33.74-22.8-15.47
Net Income
-62.72-74.73-69.39-36.6-33.74-22.8-15.47
Shares Outstanding (Basic)
282828281611
Shares Outstanding (Diluted)
282828281611
Shares Change
0.33%0.46%0.30%75.41%1045.78%0.05%-
EPS (Basic)
-2.25-2.69-2.51-1.33-2.15-16.64-11.30
EPS (Diluted)
-2.25-2.69-2.51-1.33-2.15-16.64-11.30
Free Cash Flow
-53.79-56-59.64-52.09-38.994.93-21.17
Free Cash Flow Per Share
-1.93-2.02-2.16-1.89-2.483.60-15.46
Gross Margin
---100.00%100.00%--
Operating Margin
----184.22%-590.55%--
Profit Margin
----163.57%-531.54%--
Free Cash Flow Margin
----232.76%-614.37%--
EBITDA
-58.47-70.25-65.21-33.19-31.05-21.12-14.89
EBITDA Margin
----148.32%-489.19%--
Depreciation & Amortization
4.264.484.183.412.691.680.58
EBIT
-62.72-74.73-69.39-36.6-33.74-22.8-15.47
EBIT Margin
----163.57%-531.54%--
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).